Natera, Inc. (NTRA) Stock Analysis
Breakout setup
Healthcare · Diagnostics & Research
Sell if holding. At $207.62, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Panorama NIPT, Horizon carrier screening, and Signatera; Concentration risk — Supplier: Illumina.
Natera is a diagnostics company using cell-free DNA technology for oncology, women's health, and organ health testing. Revenue was $2,306.1M in 2025 from ~3.5M tests; key products include Panorama NIPT, Horizon carrier screening, and Signatera ctDNA. It operates with a global... Read more
Sell if holding. At $207.62, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Panorama NIPT, Horizon carrier screening, and Signatera; Concentration risk — Supplier: Illumina. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Score 5.4/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPanorama NIPT, Horizon carrier screening, and Signatera10-K Item 1A: 'the significant majority of our revenues are derived from sales of our Panorama NIPT, our Horizon carrier screening, or HCS, test, and our Signatera test'
- HIGHSupplierIllumina10-K Item 1A: 'the required sequencers and reagents from our supplier, Illumina, Inc., or Illumina, who is also one of our main NIPT competitors'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02LOWBoard expanded from 10 to 11; Eric Rubin appointed as independent Class I director effective March 26, 2026. Standard non-employee director compensation. No arrangement with other persons.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $207.62, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Panorama NIPT, Horizon carrier screening, and Signatera; Concentration risk — Supplier: Illumina. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Prior stop was $193.12. Score 5.4/10, moderate confidence.
Take-profit target: $232.20 (+11.8% upside). Prior stop was $193.12. Stop-loss: $193.12.
Concentration risk — Product: Panorama NIPT, Horizon carrier screening, and Signatera; Concentration risk — Supplier: Illumina; Earnings in 6 days (event risk).
Natera, Inc. trades at a P/E of N/A (forward -303.9). TrendMatrix value score: 4.2/10. Verdict: Sell.
28 analysts cover NTRA with a consensus score of 4.3/5. Average price target: $258.
What does Natera, Inc. do?Natera is a diagnostics company using cell-free DNA technology for oncology, women's health, and organ health testing....
Natera is a diagnostics company using cell-free DNA technology for oncology, women's health, and organ health testing. Revenue was $2,306.1M in 2025 from ~3.5M tests; key products include Panorama NIPT, Horizon carrier screening, and Signatera ctDNA. It operates with a global network of 100+ lab and distribution partners.